Loading...
Last submissions
-
-
-
Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, Guilhem Roubaud, Yohann Loriot, et al.. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩. ⟨hal-03631553⟩
-
Pauline Marolleau, David Tougeron, Benoît ALLIGNET, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, In press, ⟨10.1002/ijc.34636⟩. ⟨hal-04155601⟩
-
Antonio Di Meglio, Julie Havas, Arnauld S. Gbenou, Elise Martin, Mayssam El-Mouhebb, et al.. Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40 (27), pp.3190--3204. ⟨10.1200/JCO.21.00277⟩. ⟨hal-03855946⟩
-
Marius Ilié, Julien Mazières, Emmanuel Chamorey, Simon Heeke, Jonathan Benzaquen, et al.. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16 (5), pp.807-816. ⟨10.1016/j.jtho.2021.01.1617⟩. ⟨hal-03663313⟩
-
Florence Duffaud, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, et al.. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. European Journal of Cancer, 2021, 150, pp.108-118. ⟨10.1016/j.ejca.2021.03.039⟩. ⟨hal-03623638⟩
-
Véronique Vendrely, Claire Lemanski, Pascal Pommier, Karine Le Malicot, Angélique Saint, et al.. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. Radiotherapy & Oncology, 2023, 183, pp.109542. ⟨10.1016/j.radonc.2023.109542⟩. ⟨hal-04016479⟩
-
François Quénet, Dominique Elias, Lise Roca, Diane Goéré, Laurent Ghouti, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 2021, 22 (2), pp.256-266. ⟨10.1016/s1470-2045(20)30599-4⟩. ⟨hal-03220825⟩
-
J.M. Hannoun-Lévi, M.-È. Chand, P. Blanchard, C. Chargari, A. Escande, et al.. Curiethérapie en France en 2020 : synthèse et perspectives du Groupe curiethérapie de la Société française de radiothérapie oncologique. Cancer/Radiothérapie, 2020, 24, pp.876 - 881. ⟨10.1016/j.canrad.2020.03.010⟩. ⟨hal-03493632⟩
-
Patrick Robelin, Michel Tod, Olivier Colomban, Joel Lachuer, Isabelle Ray-Coquard, et al.. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, pp.256 - 263. ⟨10.1016/j.ygyno.2020.07.021⟩. ⟨hal-03491450⟩
-
F. Derquin, A. Floquet, A.C. Hardy-Bessard, J. Edeline, J.P. Lotz, et al.. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecologic Oncology, 2020, 158 (3), pp.666-672. ⟨10.1016/j.ygyno.2020.06.491⟩. ⟨hal-02909552⟩
-
Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, Christine Lasset, et al.. Variation in breast cancer risk with mutation position smoking alcohol and chest X-ray history in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Research and Treatment, 2011, 130 (3), pp.927-938. ⟨10.1007/s10549-011-1655-3⟩. ⟨hal-00698006⟩
-
-
Guillaume Janoray, Yoann Pointreau, Marc Alfonsi, Christian Sire, Lionel Geoffrois, et al.. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. European Journal of Cancer, 2020, 133, pp.86 - 93. ⟨10.1016/j.ejca.2020.04.009⟩. ⟨hal-03490774⟩
-
Jérôme Durand-Labrunie, Anne-Sophie Baumann, Ahmet Ayav, Valérie Laurent, Emmanuel Boleslawski, et al.. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. International Journal of Radiation Oncology, Biology, Physics, 2020, 107, pp.116 - 125. ⟨10.1016/j.ijrobp.2019.12.004⟩. ⟨hal-03490661⟩
-
Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, et al.. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, 2019, 20, pp.1740 - 1749. ⟨10.1016/S1470-2045(19)30486-3⟩. ⟨hal-03489049⟩
-
-
Béatrice Bouvard, Cyrille B. Confavreux, Karine Briot, Jacques Bonneterre, Catherine Cormier, et al.. Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein. Revue du Rhumatisme, 2019, 86, pp.426 - 437. ⟨10.1016/j.rhum.2019.05.005⟩. ⟨hal-03488970⟩
-
Christophe Borg, Georges Mantion, Frank Boudghène, Françoise Mornex, François Ghiringhelli, et al.. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. Clinical Colorectal Cancer, 2019, 18, pp.200 - 208.e1. ⟨10.1016/j.clcc.2019.04.006⟩. ⟨hal-03487688⟩